Blood flow and vd (water): Both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue

Molecular Cancer Therapeutics

Volumn 8, Issue 2, 2009, Pages 303-309

  Kötz, Barbara ^a   West, Catharine ^a   Saleem, Azeem ^a   Jones, Terry ^a   Price, Patricia ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; CARBOGEN; COMBRETASTATIN A4 PHOSPHATE; FLUOROURACIL; FOLINIC ACID; NICOTINAMIDE; VASCULAR TARGETING AGENT; ANTINEOPLASTIC AGENT; CARBON DIOXIDE; OXYGEN; TUMOR MARKER; WATER;

ADULT; AGED; ARTICLE; BLOOD FLOW; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; FLUID TRANSPORT; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LIVER; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPLEEN; TISSUE PERFUSION; TISSUE PRESSURE; TUMOR BLOOD FLOW; WATER TRANSPORT; ANTIBODY SPECIFICITY; DRUG EFFECT; METABOLISM; MIDDLE AGED; NEOPLASM; PHYSIOLOGY; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBON DIOXIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NIACINAMIDE; ORGAN SPECIFICITY; OXYGEN; REGIONAL BLOOD FLOW; TUMOR MARKERS, BIOLOGICAL; WATER;

EID: 60949089007     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1016     Document Type: Article

References (38)

1. Neri D, Bicknell R. Tumor vasculature targeting. Nat Rev Cancer 2005; 5:436-46.
2. Denekamp J, Hill S, Hobson B. Vascular occlusion and tumor cell death. Eur J Cancer 1983;19:271-5.
3. Tozer G, Kanthou C, Baguley B. Disrupting tumor blood vessels. Nat Rev Cancer 2005;5:423-35.
4. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
5. Jain R. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998;4:655-7.
6. Tozer G. Measuring tumor vascular response to antivascular and antiangiogenic drugs. Br J Radiol 2003;76:S23-35.
7. O'Connor J, Jackson A, Parker G, Jayson G. DCE-MRI biomarkers in the clinical evaluation ofantiangiogenic and vascular disrupting agents. Br J Cancer 2007;96:189-95.
8. Anderson H, Yap J, Miller M, Robbins M, Jones T, Price P. Assessment of pharmacodynamic vascular response in a phase I trial of Combretastatin A4 Phosphate. J Clin Onc 2003;21:2823-30.
9. Anderson H, Price P. Clinical measurement of blood flow in tumors using positron emission tomography: a review. Nucl Med Commun 2002;23:131-8.
10. Laking G, Price P. Positron emission tomography imaging of angiogenesis and vascular function. Br J Radiol 2003;76:S50-9.
11. Jain R. Delivery of novel therapeutic agents in tumors: physiologcial barriers and strategies. J Natl Cancer Inst 1989;81:570-6.
12. Anderson H, Yap J, Wells P, et al. Measurement of renal tumor and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 2003;89:262-7.
13. Gupta N, Saleem A, Kötz B, et al. Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer. Clin Cancer Res 2006;12:3115-23.
14. Harte R, Matthews J, O'Reilly S, et al. Tumor, normal tissue, and plasma pharmacokinetic studie offluoruracil biomodulation with N-phosphonacetyl-L- aspartate, folinic acid, and interferon alfa. J Clin Oncol 1999;17:1580-9.
15. Dark G, Hill S, Prise V, Tozer G, Pettit G, Chaplin D. Combretastatin A-4, an agent that displays potent and selective toxicity towards tumor vasculature. Cancer Res 1997;57:1829-34.
16. Dickson PV, Hagedorn NL, Hamner JB, et al. IFN β-mediated vessel stabilization improves delivery and efficay of systemically administered topotecan in a murine neuroblastoma model. J Pediatr Surg 2007;42:160-5.
17. West JB, Dollery CT. Uptake ofoxygen-15-labeled CO2 compared with carbon-11-labeled CO2 in the lung. J Appl Physiol 1962;17:9-13.
18. Wilson C, Lammertsma A, McKenzie C, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992;52:1592-7.
19. Robb RA, Hanson DP. A software system for interactive and quantitative visualization of multidimensional biomedical images. Aus-tralas Phys Eng Sci Med 1991;14:9-30.
20. Cunningham V, Lammertsma A. Radioligand studies in brain: kinetic analysis of PET data. Med Chem Res 1994;4:79-96.
21. Ziegler S, Haberkorn U, Byrne H, et al. Measurement of liver blood flow using oxygen-15 labelled water and dynamic positron emission tomography: limitations of model description. Eur J Nucl Med 1996;23:169-77.
22. Jain R. Molecular regulation of vessel maturation. Nat Med 2003;9:685-93.
23. Konerding M, Malkusch W, Klapthor B, et al. Evidence for characteristic vascular patterns in solid tumors: quantitiative studies using corrosion casts. Br J Cancer 1999;80:724-32.
24. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald D. Abnormalities of basement membrane on blood vessels and endothelial sproutsin tumors. Am J Pathol 2003;163:1801-15.
25. Hashizume H, Baluk P, Morikawa S, McLean JW. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80.
26. Jain R. Intersitial transport in tumors: barriers and strategies for improvement. In: AACR 96th Annual Meeting: AACR Educational Book;2005.
27. Rowell N, Flower M, Cronin B, McCready V. Quantitative single-photon emission tomography for tumor blood flow measurement in bronchial carcinoma. Eur J Nucl Med Mol Imaging 1993;7:591-9.
28. Huber PE, BischofM, Jenne J, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005;65:3643-55.
29. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13:3942-50.
30. Iida H, Rhodes CG, DeSilva R, et al. Myocardial tissue fraction - correction for partial volume effects and measure of tissue viability. J Nucl Med 1991;32:2169-75.
31. DeSilva R, Yamamoto Y, Rhodes CG, et al. Preoperative prediction of the outcome of coronary revascularization using positron emission tomography. Circulation 1992;86:1738-42.
32. Herscovitch P, Raichle M. What is the correct value for the brain-blood partition coefficient for water? J Cereb Blood Flow Metab 1985;5:65-9.
33. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-9.
34. Saleem A, Yap J, Osman S, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging ofdrug action. Lancet 2000;355:2125-31.
35. Iida H, Tamura Y, Kitamura K, Bloomfield PM, Eberl S, Ono Y. Histochemical correlates of 15O-water-perfusable tissue fraction in experimental canine studies of old myocardial infarction. J Nucl Med 2000;41:1737-45.
36. Ley CD, Horsman MR, Kristjansen PE. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. Neoplasia 2007;9:108-12.
37. PattersonD,CharnleyN,SaleemA,etal. PhaseI evaluation of vascular disrupting agent OXi4503. J Clin Oncol 2008;26:3551.
38. Duling BR. Microvascular response to alterations in oxygen tension. Circ Res 1972;31:481-9.